CRESCENDO BIOLOGICS Trademark

Trademark Overview


On Friday, October 21, 2016, a trademark application was filed for CRESCENDO BIOLOGICS with the United States Patent and Trademark Office. The USPTO has given the CRESCENDO BIOLOGICS trademark a serial number of 79209645. The federal status of this trademark filing is REGISTERED as of Tuesday, June 12, 2018. This trademark is owned by Crescendo Biologics Limited. The CRESCENDO BIOLOGICS trademark is filed in the Chemical Products, Pharmaceutical Products, and Treatment & Processing of Materials Services categories with the following description:

Treatment and transformation of materials for others, namely the custom manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of medical therapies using antibodies and antibody fragments

Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes, namely, therapeutic pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reaction...

Chemicals used in industry and science; chemicals for laboratory research purposes, namely, chemical tests kits for in vitro testing; antibodies and antibody fragments for scientific and laboratory use in the nature of biochemical, namely, monoclonal antibodies for in vitro scientific or research use; biochemical, namely, monoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products
crescendo biologics

General Information


Serial Number79209645
Word MarkCRESCENDO BIOLOGICS
Filing DateFriday, October 21, 2016
Status700 - REGISTERED
Status DateTuesday, June 12, 2018
Registration Number5488713
Registration DateTuesday, June 12, 2018
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, March 27, 2018

Trademark Statements


Goods and ServicesTreatment and transformation of materials for others, namely the custom manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of medical therapies using antibodies and antibody fragments
Description of MarkThe mark consists of a design of three circles each having U-shaped cut-outs. The three circles are centered above the stylized wording "Crescendo" directly above the stylised wording "biologics".
Goods and ServicesPharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes, namely, therapeutic pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; monoclonal antibody therapies for therapeutic purposes, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the manufacture of therapeutic products
Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesChemicals used in industry and science; chemicals for laboratory research purposes, namely, chemical tests kits for in vitro testing; antibodies and antibody fragments for scientific and laboratory use in the nature of biochemical, namely, monoclonal antibodies for in vitro scientific or research use; biochemical, namely, monoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products
Disclaimer with Predetermined Text"BIOLOGICS"

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateMonday, June 12, 2017
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, June 12, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateMonday, June 12, 2017
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCrescendo Biologics Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressGB

Party NameCrescendo Biologics Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressGB

Party NameCrescendo Biologics Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events


Event DateEvent Description
Friday, October 27, 2023LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Saturday, August 19, 2023RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
Monday, June 12, 2023COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Saturday, October 6, 2018FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, September 18, 2018FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, September 18, 2018FINAL DISPOSITION PROCESSED
Wednesday, September 12, 2018FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, June 12, 2018REGISTERED-PRINCIPAL REGISTER
Tuesday, March 27, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 27, 2018PUBLISHED FOR OPPOSITION
Saturday, March 24, 2018NOTIFICATION PROCESSED BY IB
Wednesday, March 7, 2018NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, March 7, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 7, 2018NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Friday, February 16, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 14, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 14, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, February 14, 2018TEAS REQUEST FOR RECONSIDERATION RECEIVED
Thursday, February 1, 2018ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, February 1, 2018TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, January 12, 2018FINAL REFUSAL MAILED
Thursday, January 11, 2018FINAL REFUSAL WRITTEN
Wednesday, December 20, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 19, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, December 19, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, December 7, 2017NEW REPRESENTATIVE AT IB RECEIVED
Friday, July 14, 2017REFUSAL PROCESSED BY IB
Friday, June 23, 2017NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, June 23, 2017REFUSAL PROCESSED BY MPU
Friday, June 16, 2017APPLICATION FILING RECEIPT MAILED
Thursday, June 15, 2017NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, June 14, 2017NON-FINAL ACTION WRITTEN
Monday, June 12, 2017ASSIGNED TO EXAMINER
Monday, June 12, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 8, 2017SN ASSIGNED FOR SECT 66A APPL FROM IB